Venetoclax is an antineoplastic agent used in combination with chemotherapy. The drug is used in the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma.
Key Stages of Market Development
2016: Abbvie received FDA approval for Venclexta (Venetoclax) for treating chronic lymphocytic leukemia with 17p deletion
2018: Genentech received FDA approval for Venclexta in combination with Rituxan for patients previously treated for chronic lymphocytic leukemia and for newly diagnosed acute myeloid leukemia or those who are ineligible for intensive induction chemotherapy
2026: Several players such as Tolero Pharmaceuticals and Roche to focus on developing drug which would intensify the market competition
Future: Development of the drug for treating other types of cancers with improved efficiency
The report, at first, introduces the global Venetoclax market, including application and industry chain overview. Then, it deeply analyzes the global market by segmental and regional perspective.
In addition, the report includes a detailed pipeline analysis, recent market scenario, and cost-effective analysis of the Venetoclax with respect to other available drugs. Next, the report focuses on Venetoclax market’s competitive share analysis, company profiles, and analyst conclusion. Cumulatively, the report covers an in-depth research study on the global Venetoclax market, thanks to the market technical and marketing experts for their valuable support and assistance during this study.